Efficacy of N-163 strain of Aureobasidium pullulans-produced beta-glucan in improving muscle strength and function in patients with Duchenne muscular dystrophy; Results of a 6-month non-randomised open-label linear clinical trial

Introduction

Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive disease, whose prevalence varies between 1 in 3600 and 1 in 9300 male infants globally.¹ Loss-of-function mutations in the DMD gene prevent the production of functional dystrophin protein in patients with DMD, which causes progressive skeletal muscle weakening and degeneration, heart dysfunction, respiratory failure, and ultimately premature death.^1,2 The two treatment approaches for DMD are as follows: the first is dystrophin-targeted therapy, and the alternative is to focus on the pathological alterations that occur downstream. Gene, cell, and protein replacement therapies are examples of treatments that target dystrophin. However, dystrophin-targeted therapy can only slow the course of the disease and cannot restore the function of defective muscle tissues. Second, owing to the body’s widespread distribution of muscle tissue, dystrophin-targeted medicines have difficulty reaching all muscle tissues.³ Targeting secondary downstream pathological mechanisms is another therapeutic approach. Multiple pathogenic processes, such as fibrosis, inflammation, loss of calcium homeostasis, oxidative stress, ischaemia, and muscular atrophy, are triggered by downstream pathological mechanisms.³ Different approaches that target fibrosis, inflammation, ischaemia, etc., are available, although a wholesome approach to DMD that aims both at dystrophin replacement as well as addressing downstream pathological mechanisms is necessary.

Previously, we have reported on a 1-3,1-6 beta-glucan from the N-163 strain of the black yeast Aureobasidium pullulans that helped decrease interleukin (IL)-6, tumour growth factor (TGF)-β, and IL-13 and increase dystrophin levels along with improvement of muscle strength in patients with DMD in a clinical study performed in 28 patients with DMD for a duration of 45 days.⁴ In the same study, we reported the beneficial constitution of the gut microbiome with an increase in butyrate-producing species such as Roseburia and Faecalibacterium prausnitzii, apart from a decrease in harmful bacteria associated with inflammation such as enterobacteria and Alistipes.⁵ We also conducted a pre-clinical study of this N-163 beta-glucan in an mdx mice model, which revealed a significant decrease in inflammation score and fibrosis as well as levels of plasma alanine transaminase, aspartate aminotransferase, lactate dehydrogenase, IL-13, and haptoglobin; increased anti-inflammatory TGF-β levels; and balanced regulation of the quantity of centrally nucleated fibres indicative of muscle regeneration.⁶ In a pre-clinical study of mdx mice, we also reported muscle regeneration and maturation by MYH3 and CD44 expression.⁷ In the present study, we evaluated the effects of N-163 beta-glucan for 6 months in patients with DMD.

Materials and methods

This trial was an investigator-initiated, single-centre, randomised, open-label, prospective, linear, single-arm clinical study of patients with DMD. This study was conducted over a period of 180 days.

The intervention was consumption of one sachet of N-163 beta-glucan (Commercial name: Neu-REFIX) once daily along with conventional treatment comprising routine physiotherapy for joint mobility along with medications, viz., T. calcium and vitamin D 1000 with or without deflazacort (steroid) 6–24 mg.

Results

Altogether, 27 patients were screened, of whom 24 were included in the study. The mean ± standard deviation of age for the total study population was 11.33 ± 4.57 years (range, 5–26 years).

No adverse events were observed. No clinically significant changes from baseline data were observed on physical examination or in vital signs—temperature, blood pressure, oxygen saturation, pulse rate, or ECG (data not shown).

The mean NSAA score at pre-intervention (21.41 ± 11.81) and post-intervention (21.58 ± 11.87) did not indicate any significant change. The NSAA score improved by 1 unit in three patients and decreased by 1 unit in one patient. In the remaining patients, no change was identified (Figure 1). In the ambulatory group (n=12), the MRC score improved in 11 patients, with an average improvement of 7.09%, while it increased by 9.27% in 8 of the 12 non-ambulatory patients and decreased in 2 cases (Figure 2). The 6MWT distance improved in 9 patients, with a 29.5-metre average improvement (Figure 3).

• Download figure
• Open in new tab

Figure 1: North Star Ambulatory Assessment Score pre- and post-intervention of N-163 beta-glucan in patients with Duchenne muscular dystrophy.

• Download figure
• Open in new tab

Figure 2: Medical Research Council grading pre- and post-intervention of N-163 beta-glucan in patients with Duchenne muscular dystrophy.

• Download figure
• Open in new tab

Figure 3: Six-minute walk test score pre- and post-intervention of N-163 beta-glucan in patients with Duchenne muscular dystrophy.

Discussion

The goal of DMD treatment is to correct genetic defects and restore muscle function apart from re-establishing normal levels of dystrophin.^1-3 Despite some approaches being in clinical trials, gene correction therapies such as exon-skipping therapies are available only for a select group of patients with specific exon deletions. Although supportive treatments aim to halt or delay the disease progression, they do not significantly contribute to muscle regeneration and the restoration of muscle function, apart from the associated side effects. Even in long-term studies, only in terms of delaying the disease progression, positive outcome was reported without any improvement of muscle strength or function after the intervention compared to the baseline data in the treatment arm⁸. One of the reasons for the lack of adequate muscle regeneration is inflammation.^1-3 Since we have earlier proven the decrease in inflammation through biomarker levels in clinical and pre-clinical studies,^4-6 restoration of gut microbiome⁶, and muscle regeneration after consumption of N-163 strain of Aureobasidium pullulans produced beta-glucan evident from increased MYH3 expression and proper muscle maturation by increased CD44 hyaluronan expression in an mdx mice model,⁷ which could be attributed to the clinical improvement in muscle strength and function in the present study.

In our present study of only six months, the 6MWT distance improved in 9 patients, with a 29.5-metre average improvement. Although the NSAA scores did not indicate any significant differences pre- and post-intervention, the improvement in MRC grading in 91.6% of the participants, apart from improvement in the 6MWT indicates the significance of this N-163-produced beta-glucan approach in terms of muscle function improvement, which is not commonly observed with conventional or even other recent therapeutic approaches.

The limitations of this study are its smaller sample size and heterogeneity of the standard treatment regimens followed and a duration of six-months. Nevertheless, the safety and muscle function improvement efficacy of this N-163-produced beta-glucan food supplement without adverse reactions can be considered an indispensable addition to disease-modifying treatments for DMD and other dystrophies, such as limb-girdle muscular dystrophy.

Conclusion

This safe N-163 strain of Aureobasidium pullulans produced beta-glucan food supplement is a promising disease-modifying pharmacological adjuvant in DMD, as it improved MRC in 91.6% of the patients, with modest improvements in 6MWT and NSAA score after 6 months. In the future, a comprehensive, multi-centric clinical study should be conducted to unravel the potentials of this orally consumable, safe, and allergen-free food supplement as a drug adjuvant in delaying the progression of DMD and other dystrophies.